JP2014508720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508720A5 JP2014508720A5 JP2013543275A JP2013543275A JP2014508720A5 JP 2014508720 A5 JP2014508720 A5 JP 2014508720A5 JP 2013543275 A JP2013543275 A JP 2013543275A JP 2013543275 A JP2013543275 A JP 2013543275A JP 2014508720 A5 JP2014508720 A5 JP 2014508720A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- group
- formula
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 71
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 68
- 150000001875 compounds Chemical class 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 12
- -1 cyclopentane-1,3-diyl Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims description 6
- 102000013818 Fractalkine Human genes 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 6
- MMKZVVUZYVERKT-UHFFFAOYSA-N 5-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propyl]pyrrolo[1,2-a]quinoxalin-4-one Chemical compound C1CN(CCCN2C(C3=CC=CN3C3=CC=CC=C32)=O)CCC1(O)C1=CC=C(Cl)C=C1 MMKZVVUZYVERKT-UHFFFAOYSA-N 0.000 claims description 5
- WOSMCMULWWHMIV-UHFFFAOYSA-N 5-[3-[4-(4-chlorophenyl)piperidin-1-yl]propyl]pyrrolo[1,2-a]quinoxalin-4-one Chemical compound C1=CC(Cl)=CC=C1C1CCN(CCCN2C(C3=CC=CN3C3=CC=CC=C32)=O)CC1 WOSMCMULWWHMIV-UHFFFAOYSA-N 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 4
- MEEJEEVTIVAOJP-UHFFFAOYSA-N 5-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenylpentanenitrile Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 MEEJEEVTIVAOJP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- UWQDGCAENPSCTL-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-9h-xanthene-9-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)NC(CC1)CCN1CC1=CC=CC=C1 UWQDGCAENPSCTL-UHFFFAOYSA-N 0.000 claims description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 0 *CCC(c1ccccc1)NC(*)=O Chemical compound *CCC(c1ccccc1)NC(*)=O 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42064010P | 2010-12-07 | 2010-12-07 | |
| US61/420,640 | 2010-12-07 | ||
| PCT/US2011/063533 WO2012078633A2 (en) | 2010-12-07 | 2011-12-06 | Methods of inhibiting metastasis from cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017002396A Division JP2017122085A (ja) | 2010-12-07 | 2017-01-11 | 癌からの転移を阻害する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508720A JP2014508720A (ja) | 2014-04-10 |
| JP2014508720A5 true JP2014508720A5 (cg-RX-API-DMAC7.html) | 2015-01-29 |
| JP6076913B2 JP6076913B2 (ja) | 2017-02-08 |
Family
ID=46162450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543275A Expired - Fee Related JP6076913B2 (ja) | 2010-12-07 | 2011-12-06 | 癌からの転移を阻害する方法 |
| JP2017002396A Pending JP2017122085A (ja) | 2010-12-07 | 2017-01-11 | 癌からの転移を阻害する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017002396A Pending JP2017122085A (ja) | 2010-12-07 | 2017-01-11 | 癌からの転移を阻害する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US8435993B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2648754A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6076913B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012078633A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6076913B2 (ja) | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | 癌からの転移を阻害する方法 |
| US8883989B2 (en) * | 2011-10-18 | 2014-11-11 | Regents Of The University Of Minnesota | Fractalkine binding polynucleotides and methods of use |
| PH12021553014A1 (en) * | 2012-02-27 | 2022-09-05 | Ablynx Nv | Cx3cr1-binding polypeptides |
| JP2016534114A (ja) * | 2013-08-21 | 2016-11-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｘ３ｃｒ１標的化イメージング剤並びに疾病の診断及び処置におけるその使用 |
| WO2016024096A1 (en) * | 2014-08-11 | 2016-02-18 | Redx Pharma Plc | Antibacterial compounds |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2907489T3 (es) | 2015-12-14 | 2022-04-25 | X4 Pharmaceuticals Inc | Métodos para el tratamiento del cáncer |
| CA3009176A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2870920T3 (es) * | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
| WO2019014122A1 (en) * | 2017-07-08 | 2019-01-17 | The Brigham And Women's Hospital, Inc. | METHODS FOR ENHANCING ANTIANGIOGENIC THERAPY AND IMMUNOTHERAPY |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| KR20220090492A (ko) * | 2019-07-23 | 2022-06-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 바이시클릭 cx3cr1 수용체 작용제 |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| TW202214637A (zh) | 2020-06-11 | 2022-04-16 | 美商Ｃｈｄｉ基金會股份有限公司 | 用於亨丁頓(huntingtin)蛋白造影之雜環化合物及造影劑 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939159A (en) * | 1974-05-29 | 1976-02-17 | American Hoechst Corporation | Spiro(pyrrolo (1,2-A)quinoxalines) |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| DK0632720T3 (da) | 1992-03-25 | 1999-07-26 | Depomed Inc | Hydroxyethylcellulosebaserede depotpræparat-doseringsformer |
| DE4228095A1 (de) * | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
| WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| AU729529B2 (en) | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| US6323219B1 (en) | 1998-04-02 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for treating immunomediated inflammatory disorders |
| EP1790334A3 (en) | 1999-11-02 | 2008-02-20 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| AU2000273378A1 (en) | 2000-02-18 | 2001-08-27 | Millennium Pharmaceuticals, Inc. | Therapeutic methods that target fractalkine or cx3cr1 |
| JP2003527603A (ja) | 2000-03-16 | 2003-09-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ケモキネシス誘導物質のアッセイ |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| US20030031711A1 (en) | 2001-05-29 | 2003-02-13 | Fara John W. | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| WO2003035039A1 (en) | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| AU2002357932A1 (en) | 2001-12-18 | 2003-06-30 | Whitehead Institute For Biomedical Research | Fusion partner cells and uses thereof |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| US7919083B2 (en) | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| US20070142386A1 (en) | 2003-10-07 | 2007-06-21 | Astrazeneca | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| US20060003020A1 (en) * | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| US20060115834A1 (en) * | 2004-10-19 | 2006-06-01 | University Of Iowa Research Foundation | Methods of identifying metastatic potential in cancer |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| EP2069365A4 (en) | 2006-09-29 | 2011-11-02 | Astrazeneca Ab | NOVEL [1, 3] THIAZOLO [4,5-D] PYRIMIDIN-2 (3H) -AMINE 5,7-DISUBSTITUTED DERIVATIVES AND THEIR USE IN THERAPY |
| AU2009291749B2 (en) * | 2007-05-22 | 2015-05-21 | Chemocentryx, Inc. | 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines |
| AU2008291823B2 (en) * | 2007-08-31 | 2012-02-23 | Purdue Pharma L.P. | Substituted-quinoxaline-type-piperidine compounds and the uses thereof |
| CA2714436C (en) * | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| AR071036A1 (es) | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
| JP5351254B2 (ja) * | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| JP2011127042A (ja) | 2009-12-18 | 2011-06-30 | Fujifilm Corp | アゾ顔料、アゾ顔料の製造方法、アゾ顔料を含む分散物、及び着色組成物 |
| US8785490B2 (en) * | 2010-04-09 | 2014-07-22 | University Of Louisville Research Foundation, Inc. | Compounds for treating disease, for administering, and for pharmaceutical compositions |
| JP6076913B2 (ja) * | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | 癌からの転移を阻害する方法 |
-
2011
- 2011-12-06 JP JP2013543275A patent/JP6076913B2/ja not_active Expired - Fee Related
- 2011-12-06 EP EP11847605.0A patent/EP2648754A4/en not_active Withdrawn
- 2011-12-06 US US13/312,540 patent/US8435993B2/en active Active
- 2011-12-06 WO PCT/US2011/063533 patent/WO2012078633A2/en not_active Ceased
-
2013
- 2013-02-25 US US13/776,220 patent/US9375474B2/en active Active
-
2016
- 2016-06-06 US US15/174,227 patent/US9856260B2/en active Active
-
2017
- 2017-01-11 JP JP2017002396A patent/JP2017122085A/ja active Pending
- 2017-11-22 US US15/821,184 patent/US10414771B2/en active Active